Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

Journal of the American Academy of Dermatology

Volumn 76, Issue 6, 2017, Pages 1093-1102

  Papp, Kim ^a,b   Bachelez, Herve ^e   Costanzo, Antonio ^f   Foley, Peter ^c,g   Gooderham, Melinda ^b,h   Kaur, Primal ⁱ   Narbutt, Joanna ^j   Philipp, Sandra ^k   Spelman, Lynda ^c,l   Weglowska, Jolanta ^m   Zhang, Nan ⁱ   Strober, Bruce ^d,n  

^a K Papp Clinical Research   (Canada)

^b Probity Medical   (Canada)

^c Probity Medical Research   (Australia)

^d Probity Medical Research   (United States)

^e Universite de Paris Diderot   (France)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h Skin Centre for Dermatology   (Canada)

ⁱ AMGEN INC   (United States)

^j Dermoklinika Medical Centre   (Poland)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l Veracity Clinical Research   (Australia)

^m Regional Hospital   (Poland)

ⁿ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

more..

Author keywords

ABP 501; adalimumab; biosimilar; efficacy; equivalence; psoriasis; safety

Indexed keywords

ADALIMUMAB; ADALIMUMAB ATTO; ANTIBODY; ETANERCEPT; STEROID; USTEKINUMAB; BIOSIMILAR AGENT;

ABSCESS; ACUTE HEART INFARCTION; ADULT; APPENDICITIS; ARTICLE; BRAIN ISCHEMIA; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; METRORRHAGIA; MULTICENTER STUDY; OSTEOARTHRITIS; PATELLOFEMORAL PAIN SYNDROME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

ADALIMUMAB; ADULT; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 85014763807     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.12.014     Document Type: Article

References (34)

1. Menter, A., Gottlieb, A., Feldman, S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58 (2008), 826–850.
2. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Update 2015 EDF in cooperation with EADV and IPC. Available from: http://onlinelibrary.wiley.com/store/10.1111/jdv.13354/asset/supinfo/jdv13354-sup-0001-DataS1.pdf?v=1&s=b537740852c89200b2131f209dbd2a0af20ead88. Accessed February 15, 2017.
3. Papp, K., Gulliver, W., Lynde, C., Poulin, Y., Ashkenas, J., Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg 15 (2011), 210–219.
4. Cheng, J., Feldman, S.R., The cost of biologics for psoriasis is increasing. Drugs Context, 3, 2014, 212266.
5. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf. Accessed November 18, 2016.
6. U.S. Department of Health and Human Services. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed November 18, 2016.
7. European Medicines Agency. Guideline on similar biological medicinal products. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed November 18, 2016.
8. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Accessed November 18, 2016.
9. AMJEVITA (adalimumab-atto) injection for subcutaneous use [prescribing information], 2016, Amgen Inc, Thousand Oaks, CA.
10. show Humira (adalimumab) injection [prescribing information], 2015, AbbVie Inc, North Chicago, IL.
11. Kaur, P.P., Chow, V., Zhang, N., Moxness, M., Markus, R., Pharmacokinetic equivalence of ABP 501 relative to adalimumab: results from a randomized, single-blind, single-dose, parallel group study in healthy subjects. Arthritis Rheum 66:Suppl (2014), S661–S662 (abstract 1504).
12. Kaur, P., Chow, V., Zhang, N., Moxness, M., Markus, R., A randomized, single-blind, single-dose, three-arm, parallel group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab: results of comparison with adalimumab (EU). Ann Rheum Dis, 73(Suppl), 2014, 479 (abstract FRI0264).
13. Kaur, P., Chow, V., Zhang, N., Markus, R., A randomized, single-blind, single-dose, three-arm, parallel group study in healthy subjects demonstrating pharmacokinetic equivalence of proposed biosimilar ABP 501 with adalimumab. United European Gastroenterol J, 3(5S), 2015, A606 (abstract P1584).
14. Amgen Inc. Efficacy and safety study of ABP 501 compared to adalimumab in subjects with moderate to severe rheumatoid arthritis. Available from: https://clinicaltrials.gov/ct2/show/NCT01970475. Accessed February 16, 2017.
15. Fredriksson, T., Pettersson, U., Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157 (1978), 238–244.
16. Feldman, S.R., Krueger, G.G., Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64:suppl 2 (2005), ii65–ii68.
17. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Assay development and validation for immunogenicity testing of therapeutic protein products guidance for industry. 2016, Food and Drug Administration, Center for Drug Evaluation and Research, Silver Springs, MD.
18. Menting, S.P., Coussens, E., Pouw, M.F., et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol 151 (2015), 616–622.
19. U.S. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm. Accessed November 18, 2016.
20. Inflectra (infliximab-dyyb) [prescribing information]. 2016, Hospira, Lake Forest, IL.
21. U.S. Food and Drug Administration. FDA approves AMJEVITA, a biosimilar to Humira [press release]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522243.htm. Accessed November 18, 2016.
22. U.S. Food and Drug Administration. FDA approves Erelzi, a biosimilar to Enbrel [press release]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518639.htm. Accessed November 18, 2016.
23. Erelzi (etanercept-szzs) injection, for subcutaneous use [prescribing information], 2016, Novartis Pharma AG, Stein, Switzerland.
24. European Medicines Agency Committee for Medicinal Products for Human Use. Summary of opinion (initial authorization). Benepali etanercept. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004007/WC500196736.pdf. Accessed November 18, 2016.
25. European Medicines Agency. Remsima 100 mg powder for concentrate for solution for infusion [summary of product characteristics]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002576/WC500150871.pdf. Accessed February 16, 2017.
26. Health Canada. Remsima summary basis of decision. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_remsima_160195-eng.php. Accessed November 18, 2016.
27. Pr Inflectra. Available from: http://www.hcsc.gc.ca/dhpmps/prodpharma/sbdsmd/drugmed/sbd_smd_2014_inflectra_159493eng.php. Accessed November 18, 2016.
28. Kircik, L., Zhang, N., Kaur, P., Statistical considerations for demonstrating similarity and interpretation of clinical results in trials evaluating biosimilars. J Am Acad Dermatol, 75, 2016 (abstract 2625).
29. Menter, A., Thaci, D., Papp, K.A., et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol 73 (2015), 410–419.
30. Tracey, D., Klareskog, L., Sasso, E.H., Salfeld, J.G., Tak, P.P., Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117 (2008), 244–279.
31. Mansouri, Y., Goldenberg, G., Biologic safety in psoriasis: review of long-term safety data. J Clin Aesthet Derm 8 (2015), 30–42.
32. Saurat, J.H., Stingl, G., Dubertret, L., et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158 (2008), 558–566.
33. Menter, A., Tyring, S.K., Gordon, K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008), 106–115.
34. Cohen, S.B., Genovese, M.C., Choy, E.H., et al. Randomized, double-blind, phase 3 study of efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid arthritis. Arthritis Rheumatol, 67(suppl 10), 2015 (abstract 2054).